We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Nestle SA (PK) | USOTC:NSRGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.06% | 101.20 | 101.18 | 102.21 | 102.17 | 101.12 | 102.12 | 594,323 | 22:20:00 |
From May 2019 to May 2024
By Michael Dabaie
Aimmune Therapeutics Inc. (AIMT) shares rose 5.4% to $30.97 in midday trading.
The company said Wednesday that Nestle Health Science will make an additional $200 million equity investment. The biopharmaceutical company, focused on food allergies, said that brings Nestle's total investment in Aimmune to date to $473 million.
The Nestle Health Science investment includes the purchase of 1 million shares of Aimmune common stock and 525,634 shares of convertible preferred stock.
Nestle Health Science's total investments in Aimmune will correspond to ownership of 19.9% of Aimmune's outstanding common stock and voting power, and 25.6% overall stake in the company's fully-diluted capitalization.
The company also said it obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb7195 from Xencor Inc. (XNCR). XmAb7195, which was renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma, Aimmune said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 05, 2020 12:59 ET (17:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Nestle (PK) Chart |
1 Month Nestle (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
